Compile Data Set for Download or QSAR
maximum 50k data
Found 302 of ec50 for UniProtKB: P35408
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190292(US9180116, 38C)
Affinity DataEC50:  1.40E-7nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190296(US9180116, 39C)
Affinity DataEC50:  0.00000270nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190269(US9180116, 6D)
Affinity DataEC50: <0.00100nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM179834(US9676712, 2C)
Affinity DataEC50:  0.00100nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50213980(4-(2-((R)-2-((S)-3-hydroxyhept-1-enyl)-5-oxopyrrol...)
Affinity DataEC50:  0.00200nMAssay Description:Agonist activity at EP4 receptor expressed in HEK293 cells assessed as cAMP accumulationMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190281(US9180116, 28C-H2)
Affinity DataEC50:  0.00290nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM179991(US9676712, 4C)
Affinity DataEC50:  0.00300nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM179834(US9676712, 2C)
Affinity DataEC50:  0.00700nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μL of reduced serum medium containing 0.5% FBE. Place ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190271(US9180116, 10C)
Affinity DataEC50:  0.0100nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190275(US9180116, 28C | US9180116, 28H)
Affinity DataEC50:  0.0100nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50101858(4-(2-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxy-4-(3...)
Affinity DataEC50:  0.0100nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM179827(US9676712, 1C)
Affinity DataEC50:  0.0140nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190276(US9180116, 28D | US9180116, 28G)
Affinity DataEC50:  0.0162nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM179986(US9676712, 3C)
Affinity DataEC50:  0.0190nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM35847((15S)-prostaglandin E2 | (5Z,11alpha,13E,15S)-11,1...)
Affinity DataEC50:  0.0200nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50156547(4-(2-((R)-2-((S)-3-hydroxyoct-1-enyl)-5-oxopyrroli...)
Affinity DataEC50:  0.0200nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190270(US9180116, 9C)
Affinity DataEC50:  0.0210nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190269(US9180116, 6D)
Affinity DataEC50:  0.0230nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50373939(CHEMBL258332)
Affinity DataEC50:  0.0300nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50373942(CHEMBL272276)
Affinity DataEC50:  0.0300nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190272(US9180116, 12D)
Affinity DataEC50:  0.0350nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190268(US9180116, 2C)
Affinity DataEC50:  0.0380nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190286(US9180116, 36C)
Affinity DataEC50:  0.0380nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM238316(US9394273, 5 | US9394273, 6)
Affinity DataEC50:  0.0400nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50213980(4-(2-((R)-2-((S)-3-hydroxyhept-1-enyl)-5-oxopyrrol...)
Affinity DataEC50:  0.0400nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50156551(4-{2-[(2S)-2-[(3R)-3-[3-(4-chloro-2-methylphenyl)p...)
Affinity DataEC50:  0.0400nMAssay Description:Functional activity at human EP4 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190272(US9180116, 12D)
Affinity DataEC50:  0.0470nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50101822((Z)-7-[(1R,2R,3R)-3-Hydroxy-2-((E)-(R)-3-hydroxy-o...)
Affinity DataEC50:  0.0500nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM238319(US9394273, 10 | US9394273, 8 | US9394273, 9)
Affinity DataEC50:  0.0500nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190267(US9180116, 1F)
Affinity DataEC50:  0.0590nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190297(US9180116, 39D)
Affinity DataEC50:  0.0590nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190270(US9180116, 9C)
Affinity DataEC50:  0.0590nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190282(US9180116, 33C)
Affinity DataEC50:  0.0630nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50142481(7-[(R)-2-((E)-(S)-3-Hydroxy-oct-1-enyl)-5-oxo-pyrr...)
Affinity DataEC50:  0.0650nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190273(US9180116, 21C)
Affinity DataEC50:  0.0750nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190282(US9180116, 33C)
Affinity DataEC50:  0.0790nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190268(US9180116, 2C)
Affinity DataEC50:  0.0880nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM60734(US9156810, 23/24)
Affinity DataIC50:  44nM EC50:  0.100nMpH: 7.4 T: 2°CAssay Description:HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, EP3, or EP4 receptors were washed with TME buffer, scraped from the bot...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50213978(4-(2-((R)-2-(4-methylocta-1,3-dienyl)-5-oxopyrroli...)
Affinity DataEC50:  0.100nMAssay Description:Agonist activity at EP4 receptor expressed in HEK293 cells assessed as cAMP accumulationMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50224575((S)-4-(2-(2-(4-(3-bromophenyl)-3-hydroxybutyl)-5-o...)
Affinity DataEC50:  0.100nMAssay Description:Agonist activity at human prostaglandin EP4 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM60734(US9156810, 23/24)
Affinity DataIC50:  29nM EC50:  0.100nMpH: 7.4 T: 2°CAssay Description:HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, EP3, or EP4 receptors were washed with TME buffer, scraped from the bot...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190274(US9180116, 24D)
Affinity DataEC50:  0.110nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50101858(4-(2-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxy-4-(3...)
Affinity DataEC50:  0.142nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in intracellular cAMP level incubated for 30 mins by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190267(US9180116, 1F)
Affinity DataEC50:  0.150nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM190288(US9180116, 37C)
Affinity DataEC50:  0.150nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50224572(4-(2-(2-(4-(3-chlorophenyl)-3-hydroxybutyl)-5-oxop...)
Affinity DataEC50:  0.200nMAssay Description:Agonist activity at human prostaglandin EP4 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM184625(US9156810, 44)
Affinity DataIC50:  5.5nM EC50:  0.200nMpH: 7.4 T: 2°CAssay Description:HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, EP3, or EP4 receptors were washed with TME buffer, scraped from the bot...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM238338(US9394273, 27 | US9394273, 28)
Affinity DataEC50:  0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM238330(US9394273, 19 | US9394273, 20)
Affinity DataEC50:  0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical

US Patent
LigandPNGBDBM50156553(4-(2-((R)-2-((S,E)-5-cyclobutyl-3-hydroxypent-1-en...)
Affinity DataEC50:  0.200nMAssay Description:Functional activity at human EP4 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 302 total ) | Next | Last >>
Jump to: